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Background: Group B Neisseria meningitidis, an endotoxin-producing Gram-negative 
bacterium, causes the highest incidence of group B meningococcus (MenB) disease in 
the first year of life. The Bexsero vaccine is indicated in Europe from 8 weeks of age. 
Endotoxin components of outer membrane vesicles (OMVs) or soluble lipopolysaccha-
ride (LPS) represent a potential source of inflammation and residual reactogenicity. The 
purpose of this study was to compare novel candidate MenB vaccine formulations with 
licensed vaccines, including Bexsero, using age-specific human in vitro culture systems.
Methods: OMVs from wild type- and inactivated lpxL1 gene mutant-N. meningitidis 
strains were characterized in human neonatal and adult in vitro whole blood assays and 
dendritic cell (DC) arrays. OMVs were benchmarked against licensed vaccines, including 
Bexsero and whole cell pertussis formulations, with respect to Th-polarizing cytokine 
and prostaglandin E2 production, as well as cell surface activation markers (HLA-DR, 
CD86, and CCR7). OMV immunogenicity was assessed in mice.
results: ΔlpxLI native OMVs (nOMVs) demonstrated significantly less cytokine induc-
tion in human blood and DCs than Bexsero and most of the other pediatric vaccines 
(e.g., PedvaxHib, EasyFive, and bacillus Calmette–Guérin) tested. Despite a much 
lower inflammatory profile in vitro than Bexsero, ΔlpxLI nOMVs still had moderate DC 
maturing ability and induced robust anti-N. meningitidis antibody responses after murine 
immunization.
conclusion: A meningococcal vaccine comprised of attenuated LPS-based OMVs with 
a limited inflammatory profile in  vitro induces robust antigen-specific immunogenicity 
in vivo.
Keywords: group B meningococci, outer membrane vesicles, vaccine, newborn, dendritic cells
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inTrODUcTiOn
Human newborns and infants suffer a high frequency of infec-
tion compared to older children and adults (1), in part due to 
distinct early life immunity with impaired host defense (2). Early 
life immunization is desirable, but vaccine-induced responses of 
newborns and young infants demonstrate slow initiation, low 
immunogenicity, and reduced persistence of functional antibod-
ies and cell-mediated responses (2). Although the majority of 
global immunization schedules are focused on the pediatric age 
group, development of early life vaccines has been hampered by 
this distinct immunity and an ad  hoc approach to developing 
vaccines, relying on adult-derived results that may inaccurately 
predict infant responses (3).
Neisseria meningitidis (meningococcus) is a Gram-negative, 
endotoxin-producing organism that is a normal commensal 
of the human nasopharynx and is an important cause of 
invasive bacterial infection in children worldwide (4). Recent 
immunization programs with capsular-polysaccharide vaccines 
have dramatically reduced the incidence of serogroup C and A 
meningococcal disease in North America, Europe, and Africa 
(5). However, meningitis and septicemia caused by serogroup B 
meningococci remain a major health concern in young children, 
as similar capsule-based vaccines cannot be developed against 
this serogroup (6). Outer membrane vesicle (OMV)-based vac-
cines have historically been used, with some success, to control 
outbreaks of disease caused by serogroup B meningococci. 
OMVs are produced by the blebbing of membranes of clinical-
derived live Gram-negative bacteria during in  vitro growth 
and are useful vaccine components, as immuno-stimulatory 
membrane components [lipids, proteins, lipopolysaccharide 
(LPS), etc.] from meningococci are represented (7). As OMV 
yield from culture alone is too low for vaccine production, 
detergent extraction is used to force vesiculation and increase 
yield and has the added advantage of reducing LPS content to 
prevent overt reactogenicity. Novartis’ 4-component aluminum 
hydroxide (Alum)-adjuvanted group B meningococcus (MenB) 
vaccine (4CMenB, Trade name: Bexsero) has been licensed by 
both the European Medicines Agency and the U.S. Food and 
Drug Agency and comprised OMVs and three recombinant 
immunogenic N. meningitidis proteins identified by reverse 
vaccinology (8). Another meningococcal serogroup B vaccine, 
Trumenba, contains two recombinant proteins with no OMV 
component, is approved in the U.S. for use in individuals 10 
through 25 years of age, but lacks the potentially broader antigen 
repertoire inherent to OMVs.
The currently licensed meningococcal vaccines have the 
potential to reduce mortality and morbidity associated with 
MenB infections, but do have some limitations. Although 
detergent extraction of OMVs removes the majority of the LPS, 
the remaining endotoxin, particularly the soluble LPS, may still 
result in residual reactogenicity, necessitating the use of the 
Alum to ameliorate excess toxicity (9). Even so, immunization 
with the OMV-containing Bexsero may correlate with rates of 
reactogenicity (e.g., fever ≥38°C, tenderness at injection site) 
as common as 10% in infants less than 1 years of age (10), and 
severe reactogenicity is reported in some cases (11). Bexsero 
may also enhance reactogenicity when given together with 
other vaccines (12), prompting some primary care physicians 
to prescribe anti-inflammatory agents (13) to prevent potential 
reactions. Furthermore, as conventional assays for preclinical 
and release testing of vaccines, such as the rabbit pyrogenicity 
test and Limulus amebocyte lysate (LAL) assay, were developed 
for vaccines containing no or negligible amounts of endotoxin, 
predicting the reactogenicity of LPS-containing OMV vaccines 
is difficult and requires more sophisticated models (14).
To overcome the potential reactogenicity of wild-type (WT) 
OMV-based vaccines while maintaining the inherent adjuvant 
activity of vesicles, a vaccine has previously been developed 
using a N. meningitidis strain with genetically attenuated endo-
toxin (15). This enabled the use of detergent-free manufacturing 
processes to produce native OMVs (nOMVs) (16). To assess the 
potential of such OMV vaccines, we reasoned that it would be 
important to better understand their interactions with human 
leukocytes, including dendritic cells (DCs). DCs are professional 
antigen-presenting cells (APCs) that play a vital role in shaping 
adaptive immunity. DC maturation begins when endogenous or 
exogenous danger molecules are recognized by pattern recogni-
tion receptors [e.g., Toll-like receptors (TLRs)] triggering upregu-
lation of costimulatory molecules and production of immune 
polarizing cytokines (17). Of note, in addition to interactions 
via TLR4, N. meningitidis LPS also directly interacts with DCs 
through the C-type lectin receptor DC-SIGN and modulates 
their function (18).
In this study, we benchmarked novel candidate MenB vaccine 
formulations against licensed vaccines, including Bexsero, using 
physiologically relevant human neonatal and adult whole blood 
(WBA) and monocyte-derived dendritic cell (MoDC) in  vitro 
culture systems, both of which employ age-specific autologous 
plasma, a rich source of age-specific immunomodulatory 
molecules (2, 19). We assessed vaccine-induced production 
of Th-polarizing cytokines, upregulation of surface activation 
markers (20), and production of potential vaccine reactogenic-
ity biomarkers such as IL-1β and prostaglandin E2 (PGE2) (3, 
21, 22). We found that a meningococcal vaccine comprised of 
attenuated LPS-based OMVs with a relatively low inflamma-
tory profile toward human leukocytes in  vitro induced robust 
antigen-specific immunogenicity in vivo. Our observations, may 
inform translational development of MenB vaccines in high-risk 
populations, such as newborns and infants.
MaTerials anD MeThODs
ethics statement
Peripheral blood samples were collected after written informed 
consent from healthy adult volunteers with approval from the 
Ethics Committee of Boston Children’s Hospital, Boston, MA, 
USA (X07-05-0223). Non-identifiable cord blood samples were 
collected immediately after elective cesarean section delivery 
(epidural anesthesia) of the placenta. Births to HIV-positive or 
febrile mothers were excluded. Human experimentation guide-
lines of the U.S. Department of Health and Human Services, 
the Brigham and Women’s Hospital, Beth Israel Medical Center, 
and Boston Children’s Hospital were observed, with approval 
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from the Ethics Committee of The Brigham and Women’s 
Hospital, Boston, MA, USA (protocol number 2000-P-000117) 
and Beth Israel Deaconess Medical Center Boston, MA, USA 
(2011P-000118). Mice were obtained from Envigo (Indianapolis, 
IN, USA), and studies were approved by the Janssen Research 
and Development, LLC Institutional Animal Care and Use 
Committee.
human Blood Processing and In Vitro 
stimulation
Human blood was anti-coagulated with 20  U/ml pyrogen-free 
sodium heparin (American Pharmaceutical Partners, Inc., 
Schaumberg, IL, USA). All blood products were kept at room 
temperature and processed within 4  h from collection. Whole 
blood (WB) was mixed 1:1 with pre-warmed (37°C) RPMI 1640 
medium (Invitrogen, Carlsbad, CA, USA) and 180 μl plated in 
a 96-well U-bottom plate (Becton Dickinson, Franklin Lakes, 
NJ, USA) containing 20 μl of 10× freshly prepared treatment, as 
described previously (23).
human MoDcs
Blood was layered onto Ficoll-Hypaque gradient (GE Healthcare, 
Waukesha, WI, USA) to collect cord blood mononuclear cells 
(CBMCs) or peripheral blood mononuclear cells (PBMCs). 
Monocytes were isolated by positive CD14 selection with magnetic 
microbeads (Miltenyi Biotec, Auburn, CA, USA). Preparations 
were routinely >95% pure as assessed by flow cytometry (23–26). 
Monocytes were cultured in tissue culture dishes at 0.4 × 106 cells/
ml in RPMI media containing fresh 10% autologous platelet-poor 
plasma, supplemented with recombinant human (rh) IL-4 (50 ng/
ml) and rh granulocyte-macrophage colony-stimulating factor 
(rhGM-CSF) (100  ng/ml) (R&D Systems, Minneapolis, MN, 
USA) with one replenishment of fresh media/cytokines at day 
3. After 5–6 days, immature MoDCs were handled, as described 
previously (23, 25).
Vaccines, Tlr agonists, and Multi-analyte 
assays
Licensed vaccines were commercially obtained. Ultrapure 
LPS (Salmonella minnesota R595, List Biological Laboratories, 
Campbell, CA, USA) was used at 100 ng/ml. Supernatants were 
assayed by ELISA for TNF (BD Biosciences, San Jose, CA, USA), 
IL-1β (eBiosciences, San Diego, CA, USA) and by competitive 
monoclonal enzyme immunoassay (EIA) for PGE2 (Cayman 
Chemical, Ann Arbor, MI, USA). Additionally, assay super-
natants were analyzed by magnetic bead multiplex cytokine/
chemokine assay (Millipore, Billerica, MA, USA) and analyzed 
on the Luminex® 100/200™ System employing xPOTENT® 
software (Luminex, Austin, TX, USA) and Millipore Milliplex 
Analyst (version 3.5.5.0). PGE2 concentrations were determined 
using the analysis tool at www.myassays.com.
Flow cytometry
Monocyte-derived dendritic cells were treated with blocking 
agent for 10 min (Sigma-Aldrich), transferred to staining buffer 
[1× PBS, 0.5% (v/v) human serum albumin] and stained for 
30 min at 4°C in the dark (1 × 105 cells/staining) with fluoro-
phore-labeled antibodies [CD80/Fluorescein isothiocyanate/
Clone L307.4, CD86/phycoerythrin/Clone 2331, CCR7/V450/
Clone 150503, and HLA-DR/PerCP-Cy5.5/Clone L243 (BD 
Biosciences)]. Cells were then centrifuged (500 ×  g, 10  min), 
washed, fixed [1% (v/v) paraformaldehyde], and acquired using 
a LSRII flow cytometer employing FACSDiva software (BD 
Biosciences). Data were analyzed using the FlowJo (Tree Star, 
Inc., Ashland, OR, USA). Typically, 10,000 events per sample 
were acquired.
Production of OMVs and characterization
Outer membrane vesicles were provided by Janssen Vaccines 
and Prevention B.V. Briefly, OMVs were produced from N. 
meningitidis H44/76 (B:P1.7,16;F3-3) WT or derivatives. nOMVs 
were produced from a H44/76 ΔRΔL (15, 16, 27), resulting in 
a pentaacylated meningococcal LPS from the lpxL1 mutant N. 
meningitidis strain, lacking the secondary C12:0 acyl chain at the 
2′-position of the lipid A. Detergent-extracted OMVs were pro-
duced from the WT strain or the ΔRΔL mutant (28). Adsorption 
to aluminum hydroxide (Sigma-Aldrich) was performed, as 
described elsewhere (29). Before use, OMVs were diluted in 
10 mM Tris pH 7.4/3% (w/v) sucrose to 50 μg total protein/ml. 
OMV size was determined by dynamic light scattering (DLS) 
using the Zetasizer nanoseries (Malvern Nano-ZS, l 1/4 532 nm, 
Westborough, MA, USA).
In Vivo immunogenicity
Adult Balb/c mice (6–8 weeks, female, 10/group) were immunized 
with two doses of OMVs (2.5 μg total protein/dose), two doses 
of Bexsero [at 2.5  μg total protein/dose (equivalent to 1/10th 
human dose)], or buffer control, subcutaneously in the scruff of 
the neck. Doses were administered 4 weeks apart, with terminal 
bleed taken 2  weeks after the second dose. Serum bactericidal 
assays (SBAs) were performed, as described previously (30), 
against the WT H44/76 strain with sera from individual mice 
using baby rabbit sera (Cedarlane, Burlington, VT, USA) as an 
exogenous complement source. The H44/76 strain was chosen 
as our OMV formulations were produced from a N. meningitidis 
H44/76 strain and since H44/76 is used as an immunogenicity 
indicator strain for Bexsero approval. Reported titers are the 
reciprocal of the serum dilution giving 50% killing. If 50% killing 
was not achieved the sample was assigned a titer of 4 (half of the 
lower limit of detection).
statistical analyses and graphics
Statistical significance and graphs were generated using Prism 
v. 5.0b (GraphPad Software, La Jolla, CA, USA) and Microsoft 
Excel (Microsoft Corporation, Redmond, WA, USA). For data 
analyzed by normalization to control values, column statistics 
were conducted using the two-tailed Wilcoxon signed-rank 
test or unpaired Mann–Whitney test as appropriate. Results 
were considered significant at p <  0.05 and indicated as fol-
lows: *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ##p < 0.01, 
###p < 0.001, +p < 0.05, ++p < 0.01, and +++p < 0.001.
FigUre 1 | Depiction and characterization of Neisseria meningitidis 
outer membrane vesicles. (a) Outer membrane vesicles (OMVs) are 
composed of outer membrane lipids, proteins, and lipopolysaccharide and 
are produced by the blebbing of membranes of live Gram-negative bacteria 
during in vitro and in vivo growth [adapted from Sanders et al. (7)]. (B) 
Characterization of each OMV type used in this study, including LPS type, if 
detergent extraction was used, quantification of average size in nanometers 
and polydispersity (PdI) index.
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resUlTs
OMVs incorporating genetically 
attenuated endotoxin have reduced 
cytokine induction Potential in human 
newborn and adult Blood
Wild-type OMVs were produced from N. meningitidis H44/76 
(B:P1.7,16;F3-3), while nOMVs (Figure  1A), incorporating 
a genetically attenuated version of endotoxin, were produced 
from a H44/76 ΔRΔL mutant strain (16, 27). All OMVs were 
characterized by DLS for particle size (Figure 1B; Figure S1 in 
Supplementary Material), with all formulations falling within a 
range of 80–120 nm in diameter. Next, we tested the ability of 
(1) the commercially available Bexsero vaccine, (2) detergent-
extracted WT OMV (WT dOMV) (i.e., a Bexsero-like OMV 
formulation), (3) ΔRΔL mutant nOMV strain (ΔlpxLI nOMV) 
(28), and (4) a ΔlpxLI dOMV formulation (Figure 2A), to induce 
titration-dependent cytokine production in human neonatal 
and adult blood (Figures  2A,B). Non-detergent treated WT 
OMVs containing WT LPS were not tested as these are known 
to be highly cytotoxic. As indicated by measurement of TNF and 
IL-1β, both Bexsero and the WT dOMV robustly activated neo-
natal cord and adult peripheral blood in a titration-dependent 
manner in all concentrations tested, where levels of these two 
mediators were significantly increased over baseline (p < 0.001). 
The mutant OMVs also significantly induced production of TNF 
and IL-1β, but only at the highest concentration in newborn 
blood (p <  0.05) (Figures  2A,B; Figure S2 in Supplementary 
Material). When compared to Bexsero at the highest equivalent 
volume-to-volume (v/v) dilution tested (1:10), ΔlpxLI nOMV 
demonstrated reduced TNF production in neonatal (p < 0.001) 
and adult (p < 0.01) blood. ΔlpxLI nOMV were also less effective 
in inducing IL-1β production in newborn (p < 0.05) and WBA 
(p <  0.01). Similar trends were observed when comparing the 
ΔlpxLI nOMV to WT dOMV.
We next broadened our characterization of the ability of WT 
dOMV, ΔlpxLI dOMV, and ΔlpxLI nOMV (at v/v 1:1000–1:10) 
to induce concentration-dependent cytokine production from 
newborn and WBA using multiplexing assays (Figures  2C,D; 
Figure S3 in Supplementary Material). When compared 
head-to-head, the ΔlpxLI dOMV and ΔlpxLI nOMV induced 
markedly lower cytokine production profiles as compared to 
the WT dOMV, especially at the lowest concentration tested. 
The addition of Alum, the most commonly used adjuvant 
worldwide, and a component of the Bexsero vaccine to the 
OMV formulations altered the OMV (both wild type and 
mutant) induced innate cytokine production profiles (Figures 
S3 and S4 in Supplementary Material). Most notably, Alum 
reduced the ability of the WT dOMV to induce IFNγ and the 
chemokine CXCL10 (interferon inducible 10) (Figures S5A,B 
in Supplementary Material).
ΔlpxLI nOMV Mature human Dendritic 
cells without Bexsero-associated 
inflammatory Profile
To further characterize the innate immune effects of OMV for-
mulations, 96-well human MoDC-based arrays were generated 
after culturing CD14 selected monocytes with IL-4 and GM-CSF 
in the presence of autologous plasma, a rich source of age-specific 
soluble immunomodulatory factors (19), as described previously 
(23, 25). In response to Bexsero, a strong upregulation of CD80, 
HLA-DR (MHCII), and CCR7 and a modest increase in CD86 
were observed in both newborn and adult DCs (Figures 3A,B). 
Both the ΔlpxLI nOMV and WT dOMV (with or without Alum) 
produced slightly reduced DC maturation profiles as compared to 
the Bexsero. Interestingly, the Alum-adjuvanted ΔlpxLI nOMV 
formulation induced a similar upregulation profile to Bexsero 
in adult but not newborn MoDCs. Titration-dependent induced 
MoDC cytokine induction (Figure  3C) supported the flow 
cytometry results and mostly mirrored those observed in WB. 
When compared head-to-head, the mutant OMV formulations 
induced lower cytokine production profiles as compared to the 
WT formulations, especially at the lowest concentration tested. 
Interestingly, as seen in the WBA, the addition of Alum selectively 
enhanced WT dOMV-induced IL-1β production from human 
DCs (Figure 3D). Moreover, the addition of Alum to the ΔlpxLI 
FigUre 2 | OMVs containing genetically attenuated endotoxin demonstrate relatively low cytokine induction in human newborn and adult blood. 
Human neonatal and adult blood cultured in vitro for 6 h with buffer control (RPMI) or with increasing concentrations of wild type (WT) and mutant OMV formulations 
(1:1000–10 v/v). Supernatants were collected for ELISA (a,B) and multiplex assay [(c) newborn, (D) adult]. Results represent means ± SEM of N = 7. For analyses 
at individual treatments (e.g., control RPMI vs. Bexero 1:10), unpaired Mann–Whitney test was applied at each concentration, and statistical significances are 
denoted as follows: *p < 0.05, **p < 0.01, and ***p < 0.001. For comparison of ΔlpxLI nOMV to Bexsero, #p < 0.05, ##p < 0.01, and ###p < 0.001. For comparison 
of ΔlpxLI nOMV to WT dOMV, +p < 0.05, ++p < 0.01, and +++p < 0.001.
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nOMV formulation only induced a slight increase in IL-1β from 
newborn (Figure 3D; Figure S6A in Supplementary Material) and 
adult DCs (Figures 3E,F; Figure S6B in Supplementary Material) 
at the highest concentration tested (1:10 v/v).
ΔlpxLI nOMV are less inflammatory 
toward human leukocytes than the 
Majority of Pediatric Vaccines
To gain further insight into the inflammatory potential of the 
ΔlpxLI nOMV formulation, we next benchmarked it against a 
number of conventionally licensed pediatric vaccines (Table 
S1 in Supplementary Material) in both WB and MoDC assays. 
We have previously demonstrated that several of these licensed 
vaccines, such as the EasyFive (DTwP-HepB-Hib), induce 
distinct reactogenicity biomarker profiles in  vitro (31, 32). 
When tested at equivalent v/v treatment concentrations, ΔlpxLI 
nOMV conversely induced a lower cytokine response for most 
innate cytokines (Figures 4A,B) and chemokines (Figure S7 in 
Supplementary Material) tested, grouping closer to pediatric 
vaccines such as PCV13 and HBV, than the more inflamma-
tory (Alum +  TLR agonist)-containing pediatric vaccines (i.e., 
PedvaxHIB and EasyFive).
Next, immature newborn (Figure  5A) and adult DCs 
(Figure  5B) were assessed for vaccine-induced production of 
PGE2, a molecule whose in vitro production has been correlated 
with reactogenicity in  vivo (31–33). Of note, newborn DCs 
demonstrated significantly reduced ΔlpxLI nOMV-mediated 
PGE2 responses as compared to both Bexsero (p < 0.01) and WT 
dOMV (with Alum) (p < 0.05) (Figure 5A). A similar pattern 
was observed for adult DCs, but with significance only observed 
between Bexsero and ΔlpxLI nOMV (p < 0.01) (Figure 5B).
Newborn (Figure 5C) and adult DCs (Figure 5D) responses 
to ΔlpxLI nOMV were also benchmarked against conventional 
licensed pediatric vaccines (at 1:10 v/v, Tables S1 and S2 and 
Figure S8 in Supplementary Material) in the MoDC array. Here, 
FigUre 3 | ΔlpxLI nOMV mature human dendritic cells without the high in vitro inflammatory profile induced by Bexsero. (a) Human newborn and adult 
MoDCs were cultured in 10% autologous plasma (v/v) and stimulated for 24 h with OMV vaccines (each at 1:10 v/v). Surface expression of costimulatory molecules 
and HLA was determined by flow cytometry. (B) Average MFI of newborn and adult MoDCs. (c,D) MoDCs cultured 24 h with increasing concentrations of OMV 
vaccines (each at 1:1000, 1:100, and 1:10 v/v). (e,F) Multiplex cytokine production from treated DCs. Mean ± SEM, n = 5–6. For analyses at individual treatments 
(e.g., control RPMI vs. Bexsero), unpaired Mann–Whitney test was applied at each concentration, and statistical significances are denoted as follows: *p < 0.05, 
**p < 0.01, and not significant (NS).
6
Dowling et al. An Attenuated LPS-Based OMV Meningococcal Vaccine
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 562
we focused on the correlation of both PGE2 and IL-1β produc-
tion, as co-production of both in human monocytic assays may 
predict rabbit pyrogenicity (i.e., fever) in  vivo (33). Overall, a 
common trend was observed. The bacillus Calmette–Guérin 
(BCG) vaccine, Bexsero and WT dOMV consistently induced 
the highest production of both PGE2 and IL-1β. ΔlpxLI nOMV 
conversely induced a lower MoDC PGE2/IL-1β profile than WT 
OMV-based vaccines, suggesting similarity to low reactogenicity 
pediatric vaccines such as PCV13 and HBV (Figures 5C,D).
ΔlpxLI nOMV Dissociates inflammation 
from immunogenicity
Having characterized the relatively low reactogenicity potential 
of ΔlpxLI nOMV toward human leukocytes in  vitro, we next 
FigUre 4 | ΔlpxLI nOMV are less inflammatory in vitro than licensed combination vaccines. Human (a) neonatal and (B) adult blood cultured in vitro for 
6 h with buffer control (RPMI) or with increasing concentrations of WT and ΔlpxLI OMV formulations (each at 1:1000, 1:100, and 1:10 v/v) as well as the vaccines 
PedvaxHib, EasyFive, BCG, Cervarix, PCV13, and HBV (1:1000–10 v/v). Results for TNF, IL-1β, IL-6, IL-10, IL-12p40, and IL-12p70 are shown and represent 
means ± SEM of N = 7.
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assessed the ability of ΔlpxLI nOMV to induce immunogenicity 
in mice in vivo. Four cohorts of 10 mice each (Figure 6) were 
immunized subcutaneously with Tris/Sucrose (buffer control), 
ΔlpxLI nOMV or WT dOMV (2.5 μg total protein/dose, dOMVs 
formulated with Alum), or a 1/10th dose of Bexsero (equivalent to 
2.5 μg dOMV). Two doses were administered 4 weeks apart, with 
blood collected 2 weeks after the second dose to obtain serum 
for SBA. The buffer control alone failed to induce meningococcal 
bactericidal antibody responses. In marked contrast, Bexsero 
(p < 0.05), WT dOMV (p < 0.01), and ΔlpxLI nOMV (p < 0.01) 
all induced robust and significant antibody responses as com-
pared to baseline (Figure  6). Remarkably, even though ΔlpxLI 
nOMVs demonstrated reduced inflammation potential toward 
human leukocytes in vitro, there was no significant difference in 
immunogenicity as compared to either Bexsero or WT dOMV.
DiscUssiOn
The majority of global immunization schedules are pediatric, with 
particular focus on newborns and young infants, yet most vaccine 
discovery programs do not rationally design vaccine formula-
tions for use in humans in early life. Indeed, even when employed, 
in vitro modeling of human responses often occurs in late stage 
vaccine development. Such current pre-clinical approaches 
may contribute to vaccine formulations inducing sub-optimal 
responses in the very young (3). To more completely evaluate an 
OMV-based N. meningitidis vaccine, we took a rational vaccine 
design approach, in which we combined a relevant in vivo model 
and age-specific human in vitro culture systems that together may 
better model OMV-induced innate immunomodulatory capacity 
and immunogenicity potential. Overall, when compared to the 
WT detergent-extracted OMV (WT dOMV), mutant detergent-
extracted OMV (ΔlpxLI dOMV), and multiple licensed vaccines 
with respect to innate signaling toward human newborn and adult 
leukocytes in vitro, a prototype ΔlpxLI nOMV vaccine generated 
a pattern of response suggestive of low reactogenicity potential 
while still demonstrating robust immunogenicity in mice in vivo. 
Demonstration of non-inferior in  vivo immunogenicity of the 
ΔlpxLI nOMV vaccine, as compared to Bexsero, is noteworthy, 
especially as the in  vitro DC maturation profiles are divergent. 
Such a result may indicate that the inclusion of native endotoxin 
molecules into traditionally designed OMV-based vaccines may 
not be as essential for immunogenicity as often assumed.
A key concern regarding modern vaccine development is 
reactogenicity (33), the propensity of a formulation to cause acute 
inflammatory events either locally, such as erythema or tenderness 
FigUre 6 | ΔlpxLI nOMV induce robust immunogenicity in vivo. Mouse 
functional antibodies levels were determined by serum bactericidal assays 
(SBAs) after subcutaneous immunization with ΔlpxLI nOMV or WT dOMV 
(2.5 μg total protein/dose) formulations, as well as the vaccines Bexsero 
(1/10th human dose) or buffer control. Two doses were administered 
4 weeks apart, with terminal bleed taken 2 weeks after the second dose. 
Mutant OMV demonstrated enhanced immunogenicity over buffer control 
treatment, and equivalent induction of functional antibodies to the WT 
formulations, n = 10. Horizontal line indicates geometric mean. Wilcoxon test 
was applied between buffer and each OMV formulation, or between OMV 
formulations as indicated. Statistical significance is denoted as follows: 
*p < 0.05, **p < 0.01, and not significant (NS).
FigUre 5 | ΔlpxLI nOMV-induced lower MoDc-Pge2 and -il-1β than 
alum-adjuvanted WT OMV and the licensed Bexsero vaccine. Human 
newborn and adult MoDCs were cultured in 10% autologous plasma (v/v) 
and stimulated for 24 h with increasing concentrations of OMV vaccines 
(each at 1:1000, 1:100, and 1:10 v/v). (a) Newborn and (c) adult PGE2 
production, as measured by ELISA. Potential reactogenicity biomarker 
correlation of PGE2 with IL-1β for newborn (B) and adult (D) MoDCs after 
treatment with wild WT and mutant OMV formulations (at 1:10 v/v) as well as 
the vaccines PedvaxHib, EasyFive, BCG, Cervarix, PCV13, and HBV (at 1:10 
v/v). Mean ± SEM, n = 5–6. PGE2 levels are depicted with untreated basal 
levels subtracted. For analyses at individual treatments (e.g., Bexsero 1:10 
vs. ΔlpxLI nOMV 1:10), Wilcoxon test was applied at each concentration and 
statistical significances are denoted as follows: *p < 0.05 and **p < 0.01.
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at the injection site, or systemically, such as fever. In this context, 
in vitro assays that provide potential reactogenicity biomarker data 
may be highly advantageous in de-risking formulation selection 
for in vivo use (21). By employing an in vitro human DC array, 
we benchmarked the immunomodulatory abilities of an ΔlpxLI 
nOMV-based vaccine against several licensed pediatric vaccines. 
DCs are logical targets for such in vitro studies as they efficiently 
process antigens for induction of immunity against pathogens and 
their components (34). The few published studies that assessed the 
activating effects of OMV on human leukocytes in vitro (35–40) 
evaluated fixed concentrations with limited cytokine measure-
ments. One study evaluated concentration-dependent OMV 
responses in human WB and PBMC assays, solely from adult 
donors (39). Accordingly, our study is the first to comprehensively 
investigate (a) the ontogeny of OMV-induced immune responses 
and (b) the responses of human DCs to OMVs as benchmarked 
against licensed vaccines. ΔlpxLI nOMV induced cytokine 
responses significantly lower than those induced by either Bexsero 
or licensed vaccines (i.e., PedvaxHIB and EasyFive). As dem-
onstrated by the stronger induction of costimulatory molecule 
expression by the ΔlpxLI nOMV with Alum in adult but not 
newborn MoDCs, the dramatically enhanced human DC IL-1β 
production in response to Alum-adjuvanted WT dOMV, as well 
as our prior studies demonstrating distinct ontological effects of 
Alum on in vitro DC IL-1β production (24), it is reasonable to 
suggest that our age-specific in vitro systems may be useful tools 
with respect to characterizing candidate vaccine formulations 
with or without Alum.
Our study has multiple strengths including (a) robust age-
specific human in  vitro modeling, (b) extensive benchmarking 
to multiple licensed vaccines, and (c) confirmation of immuno-
genicity in vivo. That said, our study also has some limitations 
including (a) the unavoidable use of different species for in vitro 
(human) and in vivo (mouse) studies, (b) that in vitro systems, 
no matter how carefully developed, are imperfect models for 
responses in vivo, (c) the lack of full concordance in the antigens 
profile found in Bexsero- which contains added recombinant 
protein- and our ΔlpxLI nOMV formulations that do not, and 
(d) the lack of non-detergent treated- WT strain-derived OMVs 
that contain WT LPS. While such a formulation was initially not 
evaluated as part of our current study due to the known cytotoxic 
effects in humans, based on our results, such WT OMVs may 
provide a benchmark in future studies employing human in vitro 
systems. Of note, our experiences to date with in  vitro bench-
marking suggest that our in vitro studies provide insights relevant 
in vivo (2). Additionally, studies evaluating OMV vaccine-based 
reactogenicity in vivo using similar strategies to ours in mice (41) 
and humans (42) support these conclusions.
Several aspects of our results will prompt future investiga-
tions. For example, nucleotide-binding oligomerization domain 
(NOD)-like receptor-mediated IL-1β production is greater in 
human newborn cord than adult peripheral blood (43, 44) and 
slowly decreases to adult levels over the first years of life (45). 
A similar phenomenon for basal PGE2 levels in WB has been 
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observed (32). Therefore, further study of the IL-1β/PGE2 axis as 
a predictive marker of vaccine reactogenicity may need to take 
ontogeny into account. Recent use of proteomics (secretomics) 
has profiled hundreds of proteins released by human monocytes 
when stimulated in vitro with Alum or TLR agonists, several of 
which have been validated upon study of licensed adjuvanted 
vaccines, providing opportunities for further refinement of future 
adjuvanticity and reactogenicity biomarkers (31). Finally, the 
evaluation of different pentaacyl lipid A mutants (46) and com-
parison of their modified agonist properties using age-specific 
human WB and DC assays should also considered.
The persistently high global burden of meningococcal disease 
in the very young infants and adolescents provides a compelling 
rationale for developing additional safe and effective early life 
vaccines (47). Overall, two key aspects of our study deserve par-
ticular emphasis: (a) human in vitro systems model age-specific 
biomarker responses that may correspond to reactogenicity 
and immunogenicity as benchmarked to licensed vaccines and 
(b) these in vitro systems may enable systematic comparison of 
formulations with and without candidate adjuvants early in the 
design process to inform translational development. Overall, 
if further validated, such an approach of in vitro assay system-
informed age-specific vaccine development may open new paths 
to more precise vaccine development for distinct vulnerable 
populations.
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